Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.

ABSTRACT:

Background

Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment.

Methods

Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and physician's global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman's test for repeated measures analysis of variance.

Results

Compared to baseline, there were improvemen

SUBMITTER: Campanilho-Marques R 

PROVIDER: S-EPMC7161150 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature